NASDAQ:PRTA Prothena (PRTA) Stock Price, News & Analysis $24.43 -0.36 (-1.45%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$24.14▼$25.4150-Day Range$19.54▼$24.7952-Week Range$18.69▼$70.09Volume309,377 shsAverage Volume653,196 shsMarket Capitalization$1.31 billionP/E RatioN/ADividend YieldN/APrice Target$66.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Prothena alerts: Email Address Prothena MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside170.2% Upside$66.00 Price TargetShort InterestHealthy8.87% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.17Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.54) to ($4.52) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.15 out of 5 starsMedical Sector376th out of 936 stocksPharmaceutical Preparations Industry178th out of 436 stocks 3.4 Analyst's Opinion Consensus RatingProthena has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageProthena has only been the subject of 3 research reports in the past 90 days.Read more about Prothena's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted8.87% of the outstanding shares of Prothena have been sold short.Short Interest Ratio / Days to CoverProthena has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Prothena has recently decreased by 6.47%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldProthena does not currently pay a dividend.Dividend GrowthProthena does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRTA. Previous Next 3.4 News and Social Media Coverage News SentimentProthena has a news sentiment score of 1.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Prothena this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Prothena to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Prothena insiders have not sold or bought any company stock.Percentage Held by Insiders28.20% of the stock of Prothena is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.08% of the stock of Prothena is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Prothena's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Prothena are expected to grow in the coming year, from ($4.54) to ($4.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Prothena is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Prothena is -7.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProthena has a P/B Ratio of 2.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Prothena's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DarwinTop Stock Unveiled!Ready to discover the standout stock of 2024? We’ve identified a single buy & hold gem that’s poised to redefine your portfolio. Download our exclusive report now and dive into the Insights. Click below to opt-in and receive up to two additional free bonus subscriptions. Unsubscribe at any time.Get Your Free Report About Prothena Stock (NASDAQ:PRTA)Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.Read More PRTA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRTA Stock News HeadlinesJuly 22, 2024 | finance.yahoo.comPRTA Aug 2024 17.500 put (PRTA240816P00017500)June 7, 2024 | seekingalpha.comProthena: Potential For Future Price Drop On Failure Risk Of Late-Stage TrialsJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prothena Amid Strong Pipeline Prospects and Strategic PartnershipsMay 28, 2024 | msn.comBristol Myers licenses second compound from ProthenaMay 28, 2024 | businesswire.comProthena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development CollaborationMay 14, 2024 | finance.yahoo.comNews Flash: Analysts Just Made A Notable Upgrade To Their Prothena Corporation plc (NASDAQ:PRTA) ForecastsMay 12, 2024 | finance.yahoo.comAnalysts Have Lowered Expectations For Prothena Corporation plc (NASDAQ:PRTA) After Its Latest ResultsJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Prothena Amid Strong Pipeline and Financial HealthMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed: Prothena’s Prasinezumab Shows Promise in Slowing Parkinson’s ProgressionMay 9, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Paragon 28 (FNA), Prothena (PRTA)May 8, 2024 | investorplace.comPRTA Stock Earnings: Prothena Corp Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | tmcnet.comProthena Reports First Quarter 2024 Financial Results and Business HighlightsMay 8, 2024 | finance.yahoo.comWe think Prothena Corporation plc's (NASDAQ:PRTA) CEO May Struggle To See Much Of A Pay Rise This YearMay 7, 2024 | msn.comProthena Q1 2024 Earnings PreviewMay 7, 2024 | markets.businessinsider.comProthena is about to announce its earnings — here's what to expectMay 1, 2024 | stockhouse.comProthena to Report First Quarter 2024 Financial Results on May 8See More Headlines Receive PRTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Prothena and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PRTA CUSIPN/A CIK1559053 Webwww.prothena.com Phone(531) 236-2500Fax353-1902-3510Employees130Year FoundedN/APrice Target and Rating Average Stock Price Target$66.00 High Stock Price Target$87.00 Low Stock Price Target$28.00 Potential Upside/Downside+166.7%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-147,030,000.00 Net Margins-193.17% Pretax Margin-207.44% Return on Equity-30.48% Return on Assets-24.74% Debt Debt-to-Equity RatioN/A Current Ratio13.08 Quick Ratio13.08 Sales & Book Value Annual Sales$91.37 million Price / Sales14.57 Cash FlowN/A Price / Cash FlowN/A Book Value$10.46 per share Price / Book2.37Miscellaneous Outstanding Shares53,770,000Free Float38,608,000Market Cap$1.33 billion OptionableOptionable Beta0.21 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Gene G. Kinney Ph.D. (Age 55)President, CEO & Director Comp: $1MMr. Tran B. Nguyen M.B.A. (Age 50)CFO & Chief Strategy Officer Comp: $830.14kMr. Brandon S. Smith (Age 49)Chief Operating Officer Comp: $757.79kMs. Carol D. Karp (Age 71)Chief Regulatory Officer Comp: $701.48kDr. Hideki Garren M.D. (Age 59)Ph.D., Chief Medical Officer Comp: $808.71kMs. Karin L. Walker CPA (Age 61)Chief Accounting Officer & Controller Dr. Wagner M. Zago (Age 51)Chief Scientific Officer Comp: $478.79kMr. Mark C. Johnson C.F.A.Vice President of Investor RelationsMr. Michael J. Malecek (Age 58)Chief Legal Officer Comp: $588.25kMr. David A. Ford (Age 54)Chief People Officer More ExecutivesKey CompetitorsDynavax TechnologiesNASDAQ:DVAXUroGen PharmaNASDAQ:URGNAkebia TherapeuticsNASDAQ:AKBAPuma BiotechnologyNASDAQ:PBYIMarinus PharmaceuticalsNASDAQ:MRNSView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 19,578 shares on 7/26/2024Ownership: 0.308%SG Americas Securities LLCBought 37,852 shares on 7/12/2024Ownership: 0.101%Teachers Retirement System of The State of KentuckyBought 2,895 shares on 5/28/2024Ownership: 0.026%Artal Group S.A.Bought 500,000 shares on 5/17/2024Ownership: 1.862%Ikarian Capital LLCSold 418,400 shares on 5/17/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions PRTA Stock Analysis - Frequently Asked Questions How have PRTA shares performed this year? Prothena's stock was trading at $36.34 at the beginning of the year. Since then, PRTA shares have decreased by 32.8% and is now trading at $24.43. View the best growth stocks for 2024 here. How were Prothena's earnings last quarter? Prothena Co. plc (NASDAQ:PRTA) released its earnings results on Wednesday, May, 8th. The biotechnology company reported ($1.34) EPS for the quarter, missing analysts' consensus estimates of ($1.21) by $0.13. The biotechnology company earned $0.05 million during the quarter, compared to the consensus estimate of $3.75 million. Prothena had a negative net margin of 193.17% and a negative trailing twelve-month return on equity of 30.48%. Who are Prothena's major shareholders? Prothena's top institutional shareholders include Bank of New York Mellon Corp (0.31%) and SG Americas Securities LLC (0.10%). Insiders that own company stock include Ecor1 Capital, Llc, Gene G Kinney, Tran Nguyen, Dennis J Selkoe, Richard T Collier, Lars Ekman, Michael J Malecek, Karin L Walker, Hideki Garren, Carol D Karp, Wagner M Zago and Brandon S Smith. View institutional ownership trends. How do I buy shares of Prothena? Shares of PRTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Prothena own? Based on aggregate information from My MarketBeat watchlists, some other companies that Prothena investors own include Cara Therapeutics (CARA), ArcelorMittal (MT), Merck & Co., Inc. (MRK), Energous (WATT) and BioLineRx (BLRX). This page (NASDAQ:PRTA) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prothena Co. plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Prothena With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
